Cetya Therapeutics

Executive Summary

Cetya Therapeutics is a Delaware-based biotechnology company focused on developing innovative histone deacetylase inhibitors (HDACi) for the treatment of sickle cell disease. Founded in 2012, the company leverages its expertise in HDAC inhibition, originally derived from the natural product largazole, to create differentiated therapies. Unlike approved HDAC inhibitors that are limited to liquid tumors, Cetya aims to address unmet needs in solid tumors and non-oncology indications. Its lead candidate, CT-101, is designed to induce fetal hemoglobin production, offering a potential disease-modifying therapy for sickle cell disease. The company is privately held and headquartered in Fort Collins, Colorado.

Upcoming Catalysts (preview)

• Q4 2026IND filing for CT-10140% success
• Q3 2026Orphan Drug Designation from FDA for CT-10160% success
• Q2 2026Presentation of preclinical efficacy data for CT-101 at a scientific conference70% success